Shares of Inventiva S.A. (IVA) surged 6.70% in pre-market trading on Thursday, as investors eagerly anticipate the company's second-quarter earnings report scheduled for release after the market closes. The biopharmaceutical company, which focuses on developing oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases, has captured the attention of market participants ahead of its financial disclosure.

The significant pre-market rally suggests that investors may be optimistic about Inventiva's upcoming results. According to FactSet Research Systems Inc., analysts expect the company to report a loss of $0.63 per share for the quarter. However, the strong stock movement indicates that market sentiment might be leaning towards the possibility of better-than-expected results or positive updates on the company's drug pipeline.

As Inventiva S.A. prepares to unveil its financial performance, investors will be closely watching for any updates on the company's lead drug candidate, lanifibranor, which is currently in Phase III clinical trials for NASH. The earnings report may provide crucial insights into the progress of ongoing studies and potential milestones, which could further influence the stock's performance in the coming days.